公开(公告)号：US20230117803A1

公开(公告)日：2023-04-20

申请号：US17759906

申请日：2021-02-02

Applicant: BIONTECH SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Lena KRANZ ,  Mathias VORMEHR

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  A61P17/00 ,  A61K39/395

Abstract: The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising providing to the subject a peptide or protein vaccine and a binding agent, such as a bispecific antibody, binding to PD-L1 and CD137, such as human PD-L1 and human CD137, e.g., by co-administering to the subject a peptide or protein used for vaccination or a polynucleotide, in particular RNA, encoding a peptide or protein used for vaccination, and a binding agent binding to PD-L1 and CD137 or a polynucleotide, in particular RNA, encoding a binding agent binding to PD-L1 and CD137. The present disclosure further relates to medical preparations useful in the methods disclosed herein.

公开(公告)号：US20240335511A1

公开(公告)日：2024-10-10

申请号：US18268124

申请日：2021-12-20

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Lena Mareen KRANZ ,  Mathias VORMEHR ,  Sina FELLERMEIER-KOPF ,  Jan DIEKMANN ,  David EISEL

IPC: A61K38/20 ,  A61K9/51 ,  A61K38/38 ,  A61K48/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/765

CPC classification number: A61K38/2046 ,  A61K9/5146 ,  A61K38/2013 ,  A61K38/38 ,  A61K48/0041 ,  A61P35/00 ,  C07K14/5418 ,  C07K14/55 ,  C07K14/765 ,  C07K2319/31

Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

公开(公告)号：US20220143144A1

公开(公告)日：2022-05-12

申请号：US17442568

申请日：2020-04-02

Applicant: BIONTECH SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Inventor： Ugur SAHIN ,  Mathias VORMEHR ,  Lena KRANZ ,  Sina FELLERMEIER-KOPF ,  Alexander MUIK ,  Daniel REIDENBACH ,  Mustafa DIKEN ,  Sebastian KREITER

IPC: A61K38/20 ,  A61K38/21 ,  A61P37/04 ,  A61P35/00

Abstract: The present disclosure relates to methods and agents for enhancing the effect of immune effector cells, in particular immune effector cells that respond to interleukin-2 (IL2), for example effector T cells such as CD8+ T cells. Specifically, the present disclosure relates to methods comprising administering to a subject a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof and a polypeptide comprising type I interferon (IFN) or a functional variant thereof or a polynucleotide encoding a polypeptide comprising type I interferon or a functional variant thereof.

公开(公告)号：US20240390462A1

公开(公告)日：2024-11-28

申请号：US18268594

申请日：2021-12-20

Applicant: BIONTECH SE

Inventor： Mathias VORMEHR ,  Lena Mareen KRANZ

IPC: A61K38/20

Abstract: This disclosure relates to the field of therapeutic RNA, in particular to treat cancer. Disclosed herein are compositions, uses, and methods for reducing an unwanted response or reaction, or both, in a subject, to RNA encoding an amino acid sequence comprising a cytokine protein.